2. Search Result
Search Result
Pathways Recommended: Membrane Transporter/Ion Channel
Results for "

Nav1.7 voltage-gated sodium channel

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

3

Peptides

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6691
    Veratridine
    4 Publications Verification

    3-Veratroylveracevine

    		 Sodium Channel Neurological Disease
    Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .
    Veratridine
  • HY-125079
    DSP-2230

    ANP-230

    		 Sodium Channel Cardiovascular Disease Neurological Disease
    DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC50s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain .
    DSP-2230
  • HY-16723
    Funapide

    TV 45070; XEN402

    		 Sodium Channel Neurological Disease Inflammation/Immunology
    Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC50 values ??of 84 nM and 54 nM for Nav1.5 and Nav1.7, respectively. Funapide has analgesic effects .
    Funapide
  • HY-N1847
    3'-Methoxydaidzein

    		Sodium Channel Neurological Disease
    3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC50 of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .
    3'-Methoxydaidzein
  • HY-101789
    Nav1.7-IN-3

    		Sodium Channel Neurological Disease
    Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration .
    Nav1.7-IN-3
  • HY-119934
    NaV1.7 inhibitor-1

    		Sodium Channel Neurological Disease
    NaV1.7 inhibitor-1 is an efficacious voltage-gated sodium channel (NaV) 1.7 inhibitor with an IC50 of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5 .
    NaV1.7 inhibitor-1
  • HY-157802
    LTGO-33

    		Sodium Channel Neurological Disease
    LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .
    LTGO-33
  • HY-133910
    Lu AE98134
    1 Publications Verification

    		 Sodium Channel Neurological Disease
    Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Nav1.1 channels positive modulator. Lu AE98134 also increases the activity of Nav1.2 and Nav1.5 channels but not of Nav1.4, Nav1.6 and Nav1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Nav1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al .
    Lu AE98134
  • HY-100727
    AM-2099
    1 Publications Verification

    		 Sodium Channel Neurological Disease
    AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC50 of 0.16 μM for human Nav1.7.
    AM-2099
  • HY-A0079
    Tetracaine

    Amethocaine

    		 Sodium Channel Calcium Channel Neurological Disease
    Tetracaine (Amethocaine) is a sodium channel inhibitor and ryanodine receptor (RyR) inhibitor. Tetracaine blocks sodium conduction across nerve cell membranes, preventing rapid sodium ion influx and depolarization. Tetracaine exhibits biphasic effects on spontaneous sarcoplasmic reticulum Ca 2+ release in Ca 2+-overloaded ventricular myocytes, and increases sarcoplasmic reticulum Ca 2+ load. Tetracaine can be used in research related to eye diseases .
    Tetracaine
  • HY-156596
    Aneratrigine

    		Sodium Channel Neurological Disease
    Aneratrigine is a selective Nav1.7 inhibitor with an IC50 of 19 nM. Aneratrigine is applicable for pain-related research .
    Aneratrigine
  • HY-19366
    Nav1.7-IN-2

    		Sodium Channel Neurological Disease
    Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.
    Nav1.7-IN-2
  • HY-123825
    GX-674

    		Sodium Channel Cardiovascular Disease Neurological Disease
    GX-674 is a potent, state-dependent, isoform-selective voltage-gated sodium channel 1.7 (Nav1.7) antagonist with an IC50 of 0.1 nM at -40 mV .
    GX-674
  • HY-P10234A
    Poneratoxin acetate
    3 Publications Verification

    		 Sodium Channel Neurological Disease
    Poneratoxin acetate is the acetate salt form of Poneratoxin (HY-P10234). Poneratoxin acetate is the modulator for voltage-gated sodium channel (NaV, EC50 for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .
    Poneratoxin acetate
  • HY-108425
    AMG8379

    		Sodium Channel Neurological Disease
    AMG8379 is a potent, orally active and selective sulfonamide antagonist of the voltage-gated sodium channel NaV1.7, with IC50s of 8.5 and 18.6 nM for hNaV1.7 and mNaV1.7, respectively. AMG8379 potently and reversibly blocks endogenous Tetrodotoxin (TTX)-sensitive sodium channels in dorsal root ganglia (DRG) neurons with an IC50 of 3.1 nM .
    AMG8379
  • HY-15736
    Sodium Channel inhibitor 1

    		Sodium Channel Neurological Disease
    Sodium Channel inhibitor 1 is a state-dependent voltage-gated NaV1.7 inhibitor with an IC50 of 0.087 μM. Sodium Channel inhibitor 1 can be used for research of pain .
    Sodium Channel inhibitor 1
  • HY-N6691R
    Veratridine (Standard)

    3-Veratroylveracevine (Standard)

    		 Reference Standards Sodium Channel Neurological Disease
    Veratridine (Standard) is the analytical standard of Veratridine. This product is intended for research and analytical applications. Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39?μM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .
    Veratridine (Standard)
  • HY-P10234
    Poneratoxin

    		Sodium Channel Neurological Disease
    Poneratoxin is the modulator for voltage-gated sodium channel (NaV, EC50 for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .
    Poneratoxin
  • HY-185335
    Sodium Channel-IN-8

    		Sodium Channel Neurological Disease
    Sodium Channel-IN-8 (Example 96) is a voltage-gated sodium channel (NaV1.7) inhibitor.Sodium Channel-IN-8 can be used for the research of pain .
    Sodium Channel-IN-8
  • HY-185333
    Sodium Channel-IN-7

    		Sodium Channel Neurological Disease
    Sodium Channel-IN-7 (Example 59) is a NaV1.7 voltage-gated sodium channel inhibitor.Sodium Channel-IN-7 binds to the VSD4 binding pocket of NaV1.7, with reduced interaction with Try1537.Sodium Channel-IN-7 can be used for the research of pain .
    Sodium Channel-IN-7
  • HY-108425A
    AMG8380

    		Sodium Channel Neurological Disease
    AMG8380, an orally active and less active enantiomer of AMG8379, can serves as a negative control. AMG8380 inhibits human and mouse voltage-gated sodium channel NaV1.7 with IC50s of 0.907 and 0.387 μM, respectively. AMG8380 blocks Tetrodotoxin (TTX)-sensitive native channels with an IC50 of 2560 nM .
    AMG8380
  • HY-P5153
    ProTx-III

    μ-TRTX-Tp1a

    		 Sodium Channel Neurological Disease
    ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel Nav1.7, with an IC50 of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia .
    ProTx-III
  • HY-182831
    Nav1.7-IN-22

    		Sodium Channel Neurological Disease
    Nav1.7-IN-22 (P58 13-2) is a selective inhibitor of voltage-gated sodium channel Nav1.7. Nav1.7-IN-22 inhibits abnormal electrical signal generation and conduction in sensory neurons by blocking Nav1.7 channel activity. Nav1.7-IN-22 can be used for the study of pain .
    Nav1.7-IN-22
  • HY-100727R
    AM-2099 (Standard)

    		Sodium Channel Reference Standards Neurological Disease
    AM-2099 (Standard) is the analytical standard of AM-2099 (HY-100727). This product is intended for research and analytical applications. AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel Nav1.7 with an IC50 of 0.16 μM for human Nav1.7.
    AM-2099 (Standard)
  • HY-101789R
    Nav1.7-IN-3 (Standard)

    		Reference Standards Sodium Channel Neurological Disease
    Nav1.7-IN-3 (Standard) is the analytical standard of Nav1.7-IN-3 (HY-101789). This product is intended for research and analytical applications. Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC50 of 8 nM. Pain relief. Limited CNS penetration .
    Nav1.7-IN-3 (Standard)
  • HY-162347
    Nav1.7-IN-13

    		Sodium Channel Neurological Disease
    Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity .
    Nav1.7-IN-13
  • HY-179445
    Nav1.7-IN-20

    		Sodium Channel Neurological Disease Inflammation/Immunology
    Nav1.7-IN-20 (Compound 3AG) is an orally active Nav1.7 channel inhibitor with an IC50 of 3.1 μM. Nav1.7-IN-20 demonstrates analgesic efficacy in a complete Freund's adjuvant (CFA) inflammatory pain model. Nav1.7-IN-20 can be used for pain research .
    Nav1.7-IN-20
  • HY-183566
    MK-5661

    		Sodium Channel Neurological Disease
    MK-5661 is an orally potent NaV1.8 voltage-gated sodium channel inhibitor with an EC50 of 4.3 nM. MK-5661 selectively inhibits peripheral nociceptive signaling mediators. MK-5661 reduces capsaicin-induced spontaneous nociceptive behaviors in humanized rats and attenuates capsaicin-induced skin flushing responses in rhesus monkeys. MK-5661 is applicable for pain-related research .
    MK-5661

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: